Literature DB >> 10469854

Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients.

E M de Cavanagh1, L Ferder, F Carrasquedo, D Scrivo, A Wassermann, C G Fraga, F Inserra.   

Abstract

We previously reported chronic treatment with angiotensin-converting enzyme inhibitors (ACEis) increases antioxidant defenses in mice. In the present study, however, we examined various antioxidant defenses in chronic hemodialysis (HD) patients either treated with enalapril (10 mg/d) for at least 6 months (+ACEi; n = 11) or untreated (-ACEi; n = 11). The relationship between antioxidant status and HD was investigated by determining oxidative stress markers and antioxidant defenses in a group of chronic HD patients (n = 33) and a group of age-matched controls (n = 29). The effect of a single HD session on those parameters was also evaluated. Before an HD session (pre-HD), HD patients had significantly lower levels of red blood cell (RBC) glutathione (GSH), selenium-dependent glutathione peroxidase activity (RBC-Se-GPx), plasma ubiquinol-10, and alpha-tocopherol than controls. In a randomly selected group of patients (n = 19), a single HD session caused an additional decrease in RBC-GSH and plasma ubiquinol-10 levels. Plasma thiobarbituric acid reactive substance (TBARS) levels were significantly greater in pre-HD patients than controls. Post-HD plasma TBARS levels were similar to control values. The cohort of +ACEi HD patients had greater pre-HD RBC-GSH content, RBC-Se-GPx activity, and plasma beta-carotene concentrations than -ACEi patients (RBC-GSH: +ACEi, 3.1 +/- 0.9 micromol/mL packed RBCs [PRBCs]; -ACEi, 1.2 +/- 0.3 micromol/mL PRBCs [P < 0.05 v +ACEi]; RBC-Se-GPx: +ACEi, 5.8 +/- 0.7 U/mL PRBCs; -ACEi, 4.3 +/- 0.2 U/mL PRBCs [P < 0.05 v +ACEi]; plasma beta-carotene: +ACEi, 0.54 +/- 0.16 micromol/L plasma; -ACEi, 0.19 +/- 0.05 micromol/L plasma [P < 0.05 v +ACEi]). Results show profound alterations in the circulating antioxidant systems of chronic HD patients and that additional oxidative stress occurs during the HD procedure. In addition, in +ACEi HD patients, the levels of several antioxidant defenses are greater than in those in -ACEi HD patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469854     DOI: 10.1016/s0272-6386(99)70071-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction.

Authors:  Christy S Carter; Leanne Groban
Journal:  Aging health       Date:  2008-02-01

2.  Design of aging intervention studies: the NIA interventions testing program.

Authors:  N L Nadon; R Strong; R A Miller; J Nelson; M Javors; Z D Sharp; J M Peralba; D E Harrison
Journal:  Age (Dordr)       Date:  2008-04-18

Review 3.  Usefulness of preclinical models for assessing the efficacy of late-life interventions for sarcopenia.

Authors:  Christy S Carter; Emanuele Marzetti; Christiaan Leeuwenburgh; Todd Manini; Thomas C Foster; Leanne Groban; Philip J Scarpace; Drake Morgan
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-06-02       Impact factor: 6.053

4.  Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression.

Authors:  Zuyi Yuan; Chiharu Kishimoto; Keisuke Shioji; Hajime Nakamura; Junji Yodoi; Shigekake Sasayama
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

Review 5.  Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies.

Authors:  Rodrigo Carrasco; Rodrigo L Castillo; Juan G Gormaz; Montserrat Carrillo; Paaladinesh Thavendiranathan
Journal:  Oxid Med Cell Longev       Date:  2021-01-25       Impact factor: 6.543

6.  Effect of α -Lipoic Acid on Oxidative Stress in End-Stage Renal Disease Patients Receiving Intravenous Iron.

Authors:  Arif Showkat; William R Bastnagel; Joanna Q Hudson
Journal:  ISRN Nephrol       Date:  2014-03-05

7.  A Novel Topical Ophthalmic Formulation to Mitigate Acute Mustard Gas Keratopathy In Vivo: A Pilot Study.

Authors:  Ratnakar Tripathi; Praveen K Balne; Nishant R Sinha; Lynn M Martin; Sabeeh Kamil; James R Landreneau; Suneel Gupta; Jason T Rodier; Prashant R Sinha; Nathan P Hesemann; Alexandria C Hofmann; Michael K Fink; Shyam S Chaurasia; Rajiv R Mohan
Journal:  Transl Vis Sci Technol       Date:  2020-11-02       Impact factor: 3.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.